The purpose of this study to investigate the safety and effectiveness of nivolumab, and nivolumab combination therapy, to treat patients who have virus-associated tumors. Certain viruses have been known to play a role in tumor formation and growth. This study will investigate the effects of the study drugs, in patients who have the following types of tumors: * Anal canal cancer-No longer enrolling this tumor type * Cervical cancer * Epstein Barr Virus (EBV) positive gastric cancer-No longer enrolling this tumor type * Merkel Cell Cancer * Penile cancer-No longer enrolling this tumor type * Vaginal and vulvar cancer-No longer enrolling this tumor type * Nasopharyngeal Cancer - No longer enrolling this tumor type * Head and Neck Cancer - No longer enrolling this tumor type
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Neoadjuvant: Number of Participants With Drug-Related Select Adverse Events (AEs)
Timeframe: From first dose to 30 days post last dose (Up to 2 months)
Neoadjuvant: Number of Participants With Drug-Related Serious Adverse Events (SAEs)
Timeframe: From first dose to 30 days post last dose (Up to 2 months)
Neoadjuvant: Rate of Surgery Delay
Timeframe: Day 29
Metastatic: Investigator-Assessed Objective Response Rate (ORR)
Timeframe: From the date of first dose to the date of the initial objectively documented tumor progression or the date of the last tumor assessment prior to subsequent therapy (Up to 65 months)